Speaker(s): 

John Murray, MD, Staff Member, Geisinger - has nothing to disclose.

Mentor - Dr. Cosmin Sandulescu

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the prevalence of (+) phosphorylated alpha synuclein skin biopsy in a cohort of patients with essential tremor.​
• Discuss the implications on clinical use of p-syn testing in patients with essential tremor or essential tremor (+).

Questions to consider:

• Will this article impact your practice in any way?​
• Would you consider P-syn testing to aid in patient counseling or classification of an ET(+) case?​
• Would you consider P-syn testing in a patient with ET to estimate likelihood of developing a clinical phenotype of an alpha synucleinopathy?

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Emily Sun, DO and Cortney Houtz, LPN have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

1. Why do current AHA/ASA guidelines recommend against prophylactic ASMs after stroke — and does that mean we have proven they are harmful, or simply that we lack evidence?
2. The trial's primary endpoint included death and dropout, not just seizures. What problem does this create when trying to answer the question "does ESL prevent epilepsy?
3. ESL was given for only 30 days, but epileptogenesis after stroke unfolds over weeks to months. Does a 30-day treatment window make biological sense — and if not, what would you change?